Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Business Development


Program expansion through internal and partnered development

At Imcyse, we aim to expand the number of programs based on our platform both through in-house development and through strategic partnerships.

Advancing novel therapies together – everyday

For indications where a strategic partner will maximize the pace of development, Imcyse seeks to build strategic alliances with pharmaceutical companies that will bring their specialist knowledge and expertise in both optimizing the development of the product and knowledge in the marketplace around the globe.

Together with our partner Pfizer, for example, Imcyse is developing a novel Rheumatoid Arthritis treatment. Following a successful exploratory research collaboration, Imcyse and Pfizer are in a partnership to develop existing lead candidates and discover and optimize potential molecules after which Pfizer will lead clinical development and commercialization activities.

Broad potential beyond autoimmune diseases

The Imotope™ platform is highly adaptable and can be modified for use in a variety of diseases such as severe allergies and anti-drug antibody immunogenicity. With this potential to address indications beyond autoimmune diseases, we are in the search of new partners for a number of therapeutic areas as well as certain orphan indications.

Building on long lasting partnerships

To leverage the potential of our unique technology, Imcyse is also entering private, public and academic partnerships. In March 2020, Imcyse became a proud member of INNODIA, a global network of academic institutions, industrial partners, patient organizations and a small-sized enterprise bringing together their knowledge and experience to fight type 1 diabetes (T1D), Imcyse’s lead indication. This private-public partnership offers Imcyse greater access to T1D patients as well as to a platform of scientific exchange and technical approaches that will help the Company as it further refines treatment with ImotopesTM for patients with early T1D.

Andrew Mackie

Chief Business Officer

©imcyse 2023